Novilytic is a molecular recognition company that utilizes nanotechnology to monitor the quality of lifesaving medicines.
Our company is currently focused on the pharmaceutical bioreactor market. That concentration is based on strong monetary and regulatory interest from pharmaceutical companies to improve the production quality of a broad range of drug types called monoclonal antibodies (“T-mAbs”).
The market’s pain is that these drugs require extensive in-process testing. There is currently no instrument available to do this. The result is that these companies must spend multiple days and millions of dollars to purify their drugs prior in order to meet regulatory guidelines.
Novilytic has developed and patented new and very disruptive nanotechnology to solve this problem. The new technology is called the Proteometer™. It utilizes proprietary nanotechnology that provides near-real-time data to ensure quality. No other technology falls within this decision-making window.